English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduTwo research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.
Tag: prostate cancer
Men should check their genes for prostate cancer risk
As Prostate Cancer Awareness Month comes to a close, researchers want to circulate the message that some gene mutations linked to breast and ovarian cancer are also associated with prostate cancer.
Metastatic prostate cancer comes in two forms, which could guide treatment
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
Yale Cancer Center Study Finds New Drug Combination Shows Clinical Activity for Patients with Prostate Cancer
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer.
Q&A: How a new imaging tool helps to better stage men with prostate cancer
A paper detailing the method that led to the US Food and Drug Administration approval for PSMA PET imaging, which was led by UCLA and UCSF and their nuclear medicine teams, was recently published in JAMA Oncology.
Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment
For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Advancements in Prostate Cancer Treatments are Providing Better Outcomes for Men
Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.
Understanding Good Prostate Health for Cancer Prevention
Tina Mayer, MD, medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, shares information about prostate health.
MD Anderson Research Highlights for September 8, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.
UCLA researchers to present on latest research and clinical advancements at American Urological Association Annual Meeting
Physicians and scientists from UCLA will be joining thousands of urology experts on Sept. 10 to Sept. 13 for the virtual American Urological Association (AUA) Annual Meeting.
One-half of patients with low-risk prostate cancer switch from active surveillance to active treatment
Nearly half of men initially managed with active surveillance for “low-risk” prostate cancer transition to definitive treatment – such as surgery or radiation therapy – within a few years after diagnosis, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
Prostate cancer partnership honored for statistical excellence in accelerating therapeutic advances
The Intermediate Clinical Endpoints of Cancer of the Prostate (ICECaP) working group, led by Dana-Farber Cancer Institute researchers, is being honored by the American Statistical Association (ASA) with the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award.
Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer
Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
Genomic test could help predict aggressive disease in men newly diagnosed with prostate cancer
A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of prostate cancer progression.
Mount Sinai researchers develop novel therapy that could be effective in many cancers
New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…
Bidirectional impact of cardiovascular disease, cancer in Blacks focus of new AHA center
Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…
Prostate cancer treatment among black, white patients during pandemic
What The Study Did: This study included 647 patients with untreated nonmetastatic prostate cancer (269 patients during the pandemic and 378 from before the pandemic). During the initial COVID-19 lockdown, only 1% of Black men underwent prostatectomy, while 26% of…
MRI can cut overdiagnoses in prostate-cancer screening by half
Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine ,…
American Society for Radiation Oncology (ASTRO) to host Annual Meeting in Chicago 10/24-27
#ASTRO21 will be the first major medical conference in the city; a curated digital program also will be offered for remote attendees
Anti-androgen therapy can fuel spread of bone tumours in advanced prostate cancer
Miniature 3D bone-like tissue models show effects of anti-androgens
New AI tech for early detection of prostate cancer
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds
Tool helps predicts who will respond best to targeted prostate cancer therapy
New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
Multimodality care improves treatment outcomes for aggressive prostate cancer
Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study.
Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD
Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Education and Director of the Precision Prostatectomy Program in the Department of Urology at Icahn Mount Sinai and Center of Excellence for Prostate Cancer at The Tisch Cancer Institute.
Multimodality care improves treatment outcomes for aggressive prostate cancer
FINDINGS Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of…
Reactive oxygen species (ROS): Key components in cancer therapies
The article by Dr. Biswa Mohan Sahoo et al. is published in Anti-Cancer Agents in Medicinal Chemistry, 2021
Study Sheds Light on Persistent Racial Disparities in Prostate Cancer Care in the United States
Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.
Immunotherapy may be effective for subset of prostate cancer
Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that suggest a substantial number of patients with prostate cancer may benefit from immunotherapies.
Immunotherapy may be effective for subset of prostate cancer
Boston – In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called “hot” tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered…
BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.
PSMA-targeted radiotracer pinpoints metastatic prostate cancer across anatomic regions
Newly FDA-approved imaging agent now available for patients
Prostate cancer linked to obesity
An INRS team is investigating the relationship between body mass and the risk of developing cancer
Protein in prostate cancer may inhibit tumor growth
Research from the University of Georgia has identified a protein that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
Protein in prostate cancer may inhibit tumor growth
Researchers identified the protein responsible for cancer’s aggressiveness
Rutgers Cancer Institute of New Jersey Experts Available for Comment during Men’s Health Month
New Brunswick, N.J., June 7, 2021 – June is a special time of year focused on heightening the awareness of preventable health problems and encouraging early detection and treatment of disease for men. Diseases like prostate cancer, which is the…
Oncotarget: The drug sensitivity of hepatocellular cancer cells
‘Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months’
Mount Sinai identifies the causes of racial disparity in prostate cancer in a multi-institutional study
MEDIA ADVISORY Senior Author: Ash Tewari, MBBS, MCh, Professor and System Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Prostate Cancer…
Study finds lower mortality rate for men at high risk for death from prostate cancer who received early postoperative radiation therapy
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate Cancer
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
AI outperforms humans in creating cancer treatments, but do doctors trust it? It depends!
The impact of deploying Artificial Intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.
Oncotarget: Lung squamous cell carcinoma tumors reveal therapeutic alterations
Lung cancer is the leading cause of cancer-related deaths across the globe with more than 1.7 million deaths annually’
Oncotarget: E6-specific inhibitors as therapeutics for HPV+ head and neck carcinomas
‘Head and neck squamous cell carcinomas (HNSCC) are heterogeneous tumors that arise in the upper respiratory tract and are the 6th most common cancer worldwide by incidence’
When should screening start for men with a family history of prostate cancer?
Some men reach the risk threshold to start screening up to 11 years sooner than guidelines recommend
SWOG researchers advance cancer care at virtual ASCO 2021
“SWOG always brings an impressive portfolio of work to the ASCO annual meeting,” said SWOG Chair Charles D. Blanke, MD, “and this year I’m particularly excited about the research our investigators are presenting because it includes results that are likely…
Cleveland Clinic Researchers Identify New Drug Target for Treating Aggressive Prostate Cancer
CLEVELAND: According to new findings published in Science Translational Medicine, Cleveland Clinic researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer.
The team, led by Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, demonstrated that inhibiting the protein H6PD led to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer. The H6PD levels also were elevated in biopsied patient tumors, suggesting the protein might be targeted in patients for treatment.
Cleveland’s University Hospitals Urology Institute offers alternative prostate cancer biopsy technique
University Hospitals offers a new technique called PrecisionPoint Transperineal Access System for obtaining a prostate biopsy. The hospital will also conduct a clinical trial to determine if it offers greater benefits than a traditional biopsy.
UVA develops new tools to battle cancer, advance genomics research
University of Virginia School of Medicine scientists have developed important new resources that will aid the battle against cancer and advance cutting-edge genomics research. UVA’s Chongzhi Zang, PhD, and his colleagues and students have developed a new computational method to…
Cleveland clinic researchers identify new drug target for treating aggressive prostate cancer
Findings published in Science Translational Medicine
Racemases: The hunt for drugs to neutralise these critical enzymes
Scientists from the University of Bath in the UK explore racemases and propose strategies for finding drugs that target these important enzymes.
Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…